Clinical trial Recruiting at 1 site Observational Ages 18 and up

Personalized treatment for lung cancer patients with pleural effusion using organoids

Official title: Organoid-guided Personalized Treatment of Pleural Effusion

Run by Henan Cancer Hospital · NCT06959173 · Data updated 2026-11-12

This study is testing whether using lab-grown versions of lung cancer tumors can help doctors choose the best treatment for patients with lung cancer who have fluid buildup in their lungs.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorHenan Cancer Hospital
Government
Locations1 site (Zhengzhou, Henan)
StatusRecruiting
StartedFebruary 21, 2025
Main results expectedJanuary 2027
Study endsJanuary 2027
Registry record updatedMay 6, 2025
Trial IDNCT06959173 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and above with malignant pleural effusion and an ECOG score of 0-2.

Probably not a fit

Patients with a history of malignant tumors in the past 5 years or those with serious complications may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on lung cancer patients suffering from pleural effusion by utilizing patient-derived tumor organoids to predict drug sensitivity. The research involves acquiring clinical samples, culturing organoids in vitro, and conducting drug sensitivity tests to guide treatment decisions. By correlating the sensitivity results with clinical medication guidance, the study aims to enhance treatment plans tailored to individual patient needs. The study is conducted at a single center, Henan Cancer Hospital, with a sample capacity of 20 patients.

Why it matters

Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for lung cancer patients with pleural effusion.

How similar studies have gone: While the use of organoids for drug sensitivity testing is a growing field, this specific approach for lung cancer and pleural effusion is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

(1)18 years of age and above; (2) Understand and voluntarily sign the informed consent form (ICF), and have good compliance, and can cooperate with diagnosis and follow-up; (3)ECOG score 0-2; (4) Accompanied by malignant pleural effusion; Presence of at least one measurable lesion as assessed by the investigator;

Exclusion Criteria:

1. A history of malignant tumor in the past 5 years;
2. Complicated with serious complications, such as uncontrolled heart disease, severe arrhythmia requiring medical treatment, persistent watery diarrhea, etc.;
3. Pregnant or lactating female patients; Patients deemed unsuitable for participation in this study.

Where it's running

  • Henan cancer hospital
    Zhengzhou, Henan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.